|
1
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, et al: Safety and antitumor activity of recombinant soluble Apo2
ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bellail AC, Qi L, Mulligan P, Chhabra V
and Hao C: TRAIL agonists on clinical trials for cancer therapy:
The promises and the challenges. Rev Recent Clin Trials. 4:34–41.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang S and El-Deiry WS: TRAIL and
apoptosis induction by TNF-family death receptors. Oncogene.
22:8628–8633. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gonzalvez F and Ashkenazi A: New insights
into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29:4752–4765.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnstone RW, Frew AJ and Smyth MJ: The
TRAIL apoptotic pathway in cancer onset, progression and therapy.
Nat Rev Cancer. 8:782–798. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin CY, Park C, Hwang HJ, Kim GY, Choi BT,
Kim WJ and Choi YH: Naringenin up-regulates the expression of death
receptor 5 and enhances TRAIL-induced apoptosis in human lung
cancer A549 cells. Mol Nutr Food Res. 55:300–309. 2011. View Article : Google Scholar
|
|
7
|
Kang JL, Lee HW, Kim HJ, Lee HS,
Castranova V, Lim CM and Koh Y: Inhibition of SRC tyrosine kinases
suppresses activation of nuclear factor-kappaB, and serine and
tyrosine phosphorylation of IkappaB-alpha in
lipopolysaccharide-stimulated raw 264.7 macrophages. J Toxicol
Environ Health A. 68:1643–1662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ravindranath MH, Muthugounder S, Presser N
and Viswanathan S: Anticancer therapeutic potential of soy
isoflavone, genistein. Adv Exp Med Biol. 546:121–165. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi YH, Zhang L, Lee WH and Park KY:
Genistein-induced G2/M arrest is associated with the inhibition of
cyclin B1 and the induction of p21 in human breast carcinoma cells.
Int J Oncol. 13:391–396. 1998.PubMed/NCBI
|
|
10
|
Choi YH, Lee WH, Park KY and Zhang L:
p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin
B1 and G2/M arrest by the isoflavone genistein in human prostate
carcinoma cells. Jpn J Cancer Res. 91:164–173. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sarkar FH, Adsule S, Padhye S, Kulkarni S
and Li Y: The role of genistein and synthetic derivatives of
isoflavone in cancer prevention and therapy. Mini Rev Med Chem.
6:401–407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shao ZM, Wu J, Shen ZZ and Barsky SH:
Genistein exerts multiple suppressive effects on human breast
carcinoma cells. Cancer Res. 58:4851–4857. 1998.PubMed/NCBI
|
|
13
|
Hoffman R: Potent inhibition of breast
cancer cell lines by the isoflavonoid kievitone: Comparison with
genistein. Biochem Biophys Res Commun. 211:600–606. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peterson G and Barnes S: Genistein
inhibits both estrogen and growth factor-stimulated proliferation
of human breast cancer cells. Cell Growth Differ. 7:1345–1351.
1996.PubMed/NCBI
|
|
15
|
Kourtis N and Tavernarakis N: Autophagy
and cell death in model organisms. Cell Death Differ. 16:21–30.
2009. View Article : Google Scholar
|
|
16
|
Kroemer G and Jäättelä M: Lysosomes and
autophagy in cell death control. Nat Rev Cancer. 5:886–897. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mizushima N: Autophagy: Process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Klionsky DJ, Abeliovich H, Agostinis P,
Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA,
Ballabio A, et al: Guidelines for the use and interpretation of
assays for monitoring autophagy in higher eukaryotes. Autophagy.
4:151–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizushima N and Yoshimori T: How to
interpret LC3 immuno-blotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mizushima N, Yoshimori T and Levine B:
Methods in mammalian autophagy research. Cell. 140:313–326. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Degenhardt K, Mathew R, Beaudoin B, Bray
K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, et al:
Autophagy promotes tumor cell survival and restricts necrosis,
inflammation, and tumorigenesis. Cancer Cell. 10:51–64. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Karantza-Wadsworth V, Patel S, Kravchuk O,
Chen G, Mathew R, Jin S and White E: Autophagy mitigates metabolic
stress and genome damage in mammary tumorigenesis. Genes Dev.
21:1621–1635. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mathew R, Karantza-Wadsworth V and White
E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen N and Debnath J: Autophagy and
tumorigenesis. FEBS Lett. 584:1427–1435. 2010. View Article : Google Scholar :
|
|
25
|
Apel A, Herr I, Schwarz H, Rodemann HP and
Mayer A: Blocked autophagy sensitizes resistant carcinoma cells to
radiation therapy. Cancer Res. 68:1485–1494. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carew JS, Espitia CM, Esquivel JA II,
Mahalingam D, Kelly KR, Reddy G, Giles FJ and Nawrocki ST:
Lucanthone is a novel inhibitor of autophagy that induces cathepsin
D-mediated apoptosis. J Biol Chem. 286:6602–6613. 2011. View Article : Google Scholar :
|
|
27
|
Boya P, González-Polo RA, Casares N,
Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D,
Souquere S, Yoshimori T, et al: Inhibition of macroautophagy
triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Poole B and Ohkuma S: Effect of weak bases
on the intraly-sosomal pH in mouse peritoneal macrophages. J Cell
Biol. 90:665–669. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fan C, Wang W, Zhao B, Zhang S and Miao J:
Chloroquine inhibits cell growth and induces cell death in A549
lung cancer cells. Bioorg Med Chem. 14:3218–3222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang PD, Zhao YL, Deng XQ, Mao YQ, Shi W,
Tang QQ, Li ZG, Zheng YZ, Yang SY and Wei YQ: Antitumor and
antimetastatic activities of chloroquine diphosphate in a murine
model of breast cancer. Biomed Pharmacother. 64:609–614. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA
and Koh JY: Induction of lysosomal dilatation, arrested autophagy,
and cell death by chloroquine in cultured ARPE-19 cells. Invest
Ophthalmol Vis Sci. 51:6030–6037. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van Geelen CM, de Vries EG and de Jong S:
Lessons from TRAIL-resistance mechanisms in colorectal cancer
cells: Paving the road to patient-tailored therapy. Drug Resist
Updat. 7:345–358. 2004. View Article : Google Scholar
|
|
33
|
Srivastava RK: TRAIL/Apo-2L: Mechanisms
and clinical applications in cancer. Neoplasia. 3:535–546. 2001.
View Article : Google Scholar
|
|
34
|
Shankar S and Srivastava RK: Enhancement
of therapeutic potential of TRAIL by cancer chemotherapy and
irradiation: Mechanisms and clinical implications. Drug Resist
Updat. 7:139–156. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
LeBlanc H, Lawrence D, Varfolomeev E,
Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D and
Ashkenazi A: Tumor-cell resistance to death receptor-induced
apoptosis through mutational inactivation of the proapoptotic Bcl-2
homolog Bax. Nat Med. 8:274–281. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim H, Kim EH, Eom YW, Kim WH, Kwon TK,
Lee SJ and Choi KS: Sulforaphane sensitizes tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma
cells to TRAIL-induced apoptosis through reactive oxygen
species-mediated up-regulation of DR5. Cancer Res. 66:1740–1750.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gencel VB, Benjamin MM, Bahou SN and
Khalil RA: Vascular effects of phytoestrogens and alternative
menopausal hormone therapy in cardiovascular disease. Mini Rev Med
Chem. 12:149–174. 2012. View Article : Google Scholar :
|
|
38
|
Banerjee S, Li Y, Wang Z and Sarkar FH:
Multi-targeted therapy of cancer by genistein. Cancer Lett.
269:226–242. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sarkar FH and Li Y: Using chemopreventive
agents to enhance the efficacy of cancer therapy. Cancer Res.
66:3347–3350. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Codogno P and Meijer AJ: Autophagy and
signaling: Their role in cell survival and cell death. Cell Death
Differ. 12(Suppl 2): 1509–1518. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Klionsky DJ and Emr SD: Autophagy as a
regulated pathway of cellular degradation. Science. 290:1717–1721.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sotelo J, Briceño E and López-González MA:
Adding chloroquine to conventional treatment for glioblastoma
multiforme: A randomized, double-blind, placebo-controlled trial.
Ann Intern Med. 144:337–343. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stegehuis JH, de Wilt LH, de Vries EG,
Groen HJ, de Jong S and Kruyt FA: TRAIL receptor targeting
therapies for non-small cell lung cancer: Current status and
perspectives. Drug Resist Updat. 13:2–15. 2010. View Article : Google Scholar
|
|
44
|
Gossner G, Choi M, Tan L, Fogoros S,
Griffith KA, Kuenker M and Liu JR: Genistein-induced apoptosis and
autophagocytosis in ovarian cancer cells. Gynecol Oncol. 105:23–30.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nozawa F, Itami A, Saruc M, Kim M, Standop
J, Picha KS, Cowan KH and Pour PM: The combination of tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and
genistein is effective in inhibiting pancreatic cancer growth.
Pancreas. 29:45–52. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park SY and Seol DW: Regulation of Akt by
EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced
TRAIL-induced apoptosis. Biochem Biophys Res Commun. 295:515–518.
2002. View Article : Google Scholar : PubMed/NCBI
|
